U.S. Software Stock News

NasdaqGM:IRON
NasdaqGM:IRONBiotechs

Assessing Disc Medicine (IRON) Valuation After FDA Review Delay And Heightened Regulatory Focus

Disc Medicine (IRON) is back in focus after the FDA extended its review of the company’s experimental therapy bitopertin, citing questions around trial data integrity and potential abuse risk. See our latest analysis for Disc Medicine. Those FDA questions and the recent executive hire have played out against a softer tape, with the 7 day share price return of 9.23% and 90 day share price return of 18.63% contrasting with a 1 year total shareholder return of 21.78% and a very large 3 year...
NasdaqGM:VWAV
NasdaqGM:VWAVAerospace & Defense

Assessing VisionWave Holdings (VWAV) Valuation After European Drone Expansion And New Distribution Agreements

VisionWave Holdings (VWAV) has drawn fresh attention after Solar Drone Ltd, its wholly owned subsidiary, secured a follow-on hardware order and a new distribution agreement covering Italy and Spain for drone-enabled infrastructure services. See our latest analysis for VisionWave Holdings. The recent news pipeline, from the Solar Drone expansion across Italy and Spain to the RF technology LOI with SaverOne and the new JV platform, has come alongside a sharp pullback, with a 1 day share price...
NYSE:BXMT
NYSE:BXMTMortgage REITs

A Look At Blackstone Mortgage Trust’s (BXMT) Valuation After Securing Paramount As First Tenant At Sunset Pier 94 Studios

Blackstone Mortgage Trust (BXMT) is in focus after affiliate Blackstone Real Estate, together with its partners, secured Paramount Television Studios as the first tenant at Manhattan’s new Sunset Pier 94 Studios ahead of its opening. See our latest analysis for Blackstone Mortgage Trust. The Paramount lease lands at a time when Blackstone Mortgage Trust’s share price has been relatively steady at around $19.62, with a 90 day share price return of 9.73% and a 1 year total shareholder return of...
NYSE:BLX
NYSE:BLXDiversified Financial

Will Bladex’s Tech-Driven Trade Platform Pivot Reshape Banco Latinoamericano de Comercio Exterior’s (BLX) Core Narrative?

Banco Latinoamericano de Comercio Exterior (Bladex) recently announced it had hosted a virtual investor day on March 24, 2026, where leadership reviewed progress on its 2022–2026 plan and outlined its roadmap through 2030. A key theme from the event was Bladex’s push to evolve from a specialized trade lender into a broader transactional trade banking platform for Latin America, emphasizing scalable, technology-enabled, fee-based services. We’ll now examine how Bladex’s shift toward a...
NasdaqGS:BOKF
NasdaqGS:BOKFBanks

BOK Financial (BOKF) Net Interest Margin Strengthens Bullish Narratives In FY 2025 Results

BOK Financial (BOKF) just closed out FY 2025 with fourth quarter revenue of US$589.6 million and basic EPS of US$2.91, backed by net income of US$177.3 million. Over the past year, revenue has moved from US$523.1 million in Q4 2024 to US$589.6 million in Q4 2025, while trailing twelve month EPS sits at US$9.23. With a net interest margin of 2.98% and a cost to income ratio of 64.89% in the latest quarter, the focus this season is on how efficiently the bank is turning that top line into...
NasdaqGM:HIFS
NasdaqGM:HIFSBanks

Hingham Institution For Savings FY 2025 Net Interest Margin Rebound Challenges Bearish Narratives

How Hingham Institution for Savings' FY 2025 Numbers Set Up the Earnings Story Hingham Institution for Savings (HIFS) closed FY 2025 with fourth quarter total revenue of US$34.5 million and basic EPS of US$9.49, while trailing twelve month revenue reached US$102.8 million and EPS came in at US$25.01, setting a clear earnings marker for investors to work from. Over the past year, revenue has moved from US$65.5 million and EPS of US$12.95 on a trailing basis in Q4 2024 to US$102.8 million and...
NYSE:NSA
NYSE:NSASpecialized REITs

Is National Storage Affiliates (NSA) Pricing Reflect Future Cash Flows After Recent Share Price Rebound

If you are wondering whether National Storage Affiliates Trust is offering good value at its current price, this article walks through the key numbers to help you frame that question clearly. The stock most recently closed at US$33.80, with returns of 7.7% over the last week, 17.7% over the last month, 21.2% year to date, but a 1% decline over the past year. Those moves sit against a backdrop of ongoing interest in self storage real estate investment trusts and investor focus on how income...
NasdaqGS:EQIX
NasdaqGS:EQIXSpecialized REITs

Is Equinix (EQIX) Offering Value After Mixed Recent Share Price Performance

If you are wondering whether Equinix at around US$801.78 is priced high, low, or somewhere in between, you are not alone. That is exactly what this article will unpack. The stock has seen a 0.2% move over the last 7 days, a 7.8% return over the last 30 days, a 4.9% return year to date, but a 10.4% decline over the last year. Taken together, this gives a mixed picture of recent sentiment. These shifts sit against a backdrop of ongoing interest in data centers and digital infrastructure, where...
NYSE:GIC
NYSE:GICTrade Distributors

A Look At Global Industrial (GIC) Valuation After Weak Q3 Revenue And Earnings Misses

Global Industrial (GIC) recently reported third quarter results, with revenue, EBITDA, and EPS all coming in below analyst expectations. The company also posted the weakest revenue growth in its peer group, prompting an 11.1% share price decline. See our latest analysis for Global Industrial. At a latest share price of $31.4, Global Industrial’s 1 day share price return of a 0.79% decline and 90 day share price return of a 9.54% decline contrast with a 1 year total shareholder return of...
NasdaqGS:NAVI
NasdaqGS:NAVIConsumer Finance

Assessing Navient (NAVI) Valuation After Leadership Reshuffle And New CFO Appointment

Navient (NAVI) is back in focus after a leadership shake up that puts long time executive Steve Hauber in the Chief Financial Officer seat, consolidating oversight of finance, legal, risk and compliance. See our latest analysis for Navient. That reshuffle comes as Navient’s share price sits at US$12.51, with a 30 day share price return of 5.23% decline and a 1 year total shareholder return of 5.70% decline. This suggests recent momentum has softened even as investors weigh the upcoming 2025...
NasdaqGS:HWKN
NasdaqGS:HWKNChemicals

Is It Too Late To Consider Hawkins (HWKN) After Its Multi Year Share Price Surge

If you are wondering whether Hawkins at around US$152 is still attractively priced after a strong multi year run, this breakdown is designed to help you size up the current valuation with clear, practical checks. The share price has seen a 6.6% gain over the last 30 days, a 4.6% return year to date, and a 33.7% return over the past year, while the 3 year return is very large at close to 3x. These moves have drawn more attention to how the market is treating specialty chemical suppliers like...
NYSE:RRC
NYSE:RRCOil and Gas

How Range Resources’ High-Coupon Debt Redemption and Revolver Use Could Shape RRC Investors’ Outlook

On December 31, 2025, Range Resources Corporation announced it would fully redeem its US$600,000,000 8.25% senior notes due 2029 on January 15, 2026, at 101.375% of par plus accrued interest, funded via its existing revolving credit facility. This move retires high-coupon debt while shifting funding to shorter-term bank borrowing, putting the company’s balance sheet choices under closer investor and analyst scrutiny. Next, we’ll examine how funding this bond redemption through the revolving...
NasdaqGS:EWTX
NasdaqGS:EWTXPharmaceuticals

Is Edgewise Therapeutics (EWTX) Quietly Redefining Its Risk Profile With an Integrated Muscle-Heart Strategy?

Earlier this week, Edgewise Therapeutics used its presentation at the 44th J.P. Morgan Healthcare Conference to outline 2026 milestones, including pivotal GRAND CANYON data for sevasemten in Becker muscular dystrophy, Phase 2 readouts for EDG-7500 in hypertrophic cardiomyopathy, and continued development of its early-stage heart failure candidate EDG-15400. A distinctive aspect of the update is Edgewise’s attempt to build an integrated neuromuscular and cardiovascular franchise, with...
NasdaqGS:MRX
NasdaqGS:MRXCapital Markets

Assessing Marex Group (MRX) Valuation After Upbeat Analyst Earnings Revisions

Recent analyst reports on Marex Group (MRX) highlight increased optimism around the company’s earnings outlook. Several firms have revised their forecasts higher and reiterated positive ratings, drawing fresh attention to the stock. See our latest analysis for Marex Group. The recent earnings optimism has coincided with a 32.28% 90 day share price return and a 21.80% total shareholder return over the past year, suggesting momentum has been building around Marex Group, which had a last close...
NasdaqGS:DYN
NasdaqGS:DYNBiotechs

A Look At Dyne Therapeutics (DYN) Valuation As Strong Buy Ratings Follow Neuromuscular Program Updates

Dyne Therapeutics (DYN) is back in focus after its appearance at the 44th Annual J.P. Morgan Healthcare Conference, where CEO John G. Cox outlined progress in programs targeting myotonic dystrophy type 1 and Duchenne muscular dystrophy. See our latest analysis for Dyne Therapeutics. Despite recent enthusiasm around Dyne’s neuromuscular programs and conference visibility, the 30 day share price return of 11.61% and year to date share price return of 9.70% contrast with a 1 year total...
NasdaqGM:STAA
NasdaqGM:STAAMedical Equipment

STAAR Surgical (STAA) Valuation After Failed Alcon Deal And Boardroom Overhaul

Why STAAR Surgical Is Back in Focus After the Failed Alcon Deal STAAR Surgical (STAA) is back on investors’ radar after shareholders rejected its cash sale to Alcon and the company confirmed it will continue as an independent, publicly traded business. That decision has quickly been followed by a broad refresh of the boardroom, new committee structures and an active search for a new chief executive, all with heavy involvement from STAAR’s largest shareholders. See our latest analysis for...
NYSE:WOR
NYSE:WORMachinery

Assessing Worthington Enterprises (WOR) Valuation After Recent Share Price Weakness

Why Worthington Enterprises is on investors’ radar today Worthington Enterprises (WOR) has been drawing attention after a mixed stretch in recent trading, with the share price drifting lower over the past month and past 3 months while longer term returns remain positive. See our latest analysis for Worthington Enterprises. At around US$53.43, the share price has eased in the short term, with a 1 day share price return of a 2.0% decline and a 90 day share price return of a 5.5% decline, while...
NasdaqCM:PCT
NasdaqCM:PCTChemicals

PureCycle Technologies (PCT) Valuation Check After High Profile College Football Recycling Partnership

Event context and why it matters for PureCycle PureCycle Technologies (PCT) is in focus after partnering with Churchill Container and 4ocean to supply reusable Run It Back souvenir cups made with its recycled resin at the College Football Playoff National Championship. The program ties every 20 cups sold to the removal of one pound of ocean trash, giving PureCycle a high profile platform for its recycling technology and putting a clear environmental metric in front of fans and investors. See...
NYSE:MTB
NYSE:MTBBanks

M&T Bank (MTB) Margin Improvement Reinforces Bullish Narratives Despite Slow Growth Forecasts

M&T Bank (MTB) closed out FY 2025 with fourth quarter revenue of US$2.4 billion and basic EPS of US$4.71, alongside net income of US$718 million, framing a year where the trailing 12 month tally reached US$9.2 billion of revenue and US$17.10 in EPS. Over the past few quarters, revenue has moved from US$2.2 billion in Q4 2024 to US$2.4 billion in Q4 2025, while quarterly EPS increased from US$3.88 to US$4.71, supported by higher net income. This sets up a results season in which investors are...
NasdaqGM:RAPP
NasdaqGM:RAPPPharmaceuticals

Rapport Therapeutics (RAPP) Is Down 7.4% After Advancing RAP-219 Toward Phase 3 In Epilepsy

In early January 2026, Rapport Therapeutics announced past and planned advances across its clinical pipeline, including preparing a Phase 3 program for RAP-219 in focal onset seizures, expanding into primary generalized tonic-clonic seizures, and resuming its Phase 2 diabetic peripheral neuropathic pain trial after the FDA lifted a clinical hold. A key insight is that Rapport is concentrating resources on programs it believes can meaningfully address unmet neurological needs while supporting...
OTCPK:NODB
OTCPK:NODBBanks

North Dallas Bank & Trust (OTCPK:NODB) Margin Rebound Challenges Longstanding Bearish Narratives

North Dallas Bank & Trust (NODB) just wrapped up FY 2025 with fourth quarter total revenue of US$12.9 million and basic EPS of US$1.19, capping a trailing twelve month stretch that sums to US$48.0 million in revenue and EPS of US$3.35. Over the past few quarters, revenue has moved from US$9.8 million in Q3 2024 to US$12.9 million in Q4 2025. Quarterly EPS has ranged from US$0.20 in Q3 2024 to US$1.19 most recently, alongside reported profit growth of 166.6% and a net profit margin that...
NYSE:PRKS
NYSE:PRKSHospitality

How Investors Are Reacting To United Parks & Resorts (PRKS) 2026 SeaWorld Concert-Centered Guest Experience

United Parks & Resorts recently announced that SeaWorld returned in early 2026 with an expanded coast-to-coast live music series, offering full-length concerts by artists such as Flo Rida, Boyz II Men, and The Beach Boys in Orlando, San Diego, and San Antonio at no extra cost beyond park admission. This move places live entertainment at the center of the guest experience and is designed to deepen Annual Pass value by giving members flexible, season-long access to multiple concerts across...
NYSE:SEM
NYSE:SEMHealthcare

Does Select Medical’s Medicare Lobbying Push Change The Bull Case For Select Medical Holdings (SEM)?

In Q4 2025, Select Medical Holdings Corporation disclosed spending US$630,000 on lobbying related to regulations for long-term acute care hospitals, inpatient rehabilitation facilities, and outpatient rehabilitation clinics, with a particular focus on Medicare payment issues, while institutional investors showed mixed positioning and analysts recently issued positive ratings. This combination of targeted policy engagement and favorable analyst sentiment highlights how regulatory influence...
NYSE:ICL
NYSE:ICLChemicals

Earnings Upgrade And Higher Forecasts Might Change The Case For Investing In ICL Group (ICL)

ICL Group was recently upgraded by Zacks to a Rank #2 (Buy) after analysts raised their earnings estimates, with the consensus forecast climbing 11.1% over the past three months, signaling a more favorable earnings outlook than previously expected. This upward revision in earnings expectations suggests analysts see improving profit potential for ICL’s specialty minerals and chemicals portfolio, which could influence how investors view the company’s longer-term business prospects and risk...